AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.

$9.73  +1.84 (23.26%)
As of 04/09/2021 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  The Netherlands
IPO date:  09/12/2014
Outstanding shares:  98,119,675
Average volume:  5,644,836
Market cap:   $955,685,635
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N01045108
ISIN:        NL0010872420
Sedol:      BQQF5R2
Valuation   (See tab for details)
PE ratio:   -24.20
PB ratio:   15.41
PS ratio:   35.58
Return on equity:   -83.98%
Net income %:   -175.17%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy